You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)擬1.1億美元收購比利時呼吸道疾病設備提供商
格隆匯 03-23 16:56

格隆匯 3 月 23日丨中國生物製藥(01177.HK)宣佈,2021年3月22日,公司附屬公司C-Lab International Limited訂立協議以1.1億美元作價,以及與監管和商業里程碑有關的額外付款收購100% SOFTHALE NV("Softhale")。Softhale是一家比利時私營公司,致力於開發用於治療呼吸道疾病的產品。它的下一代軟霧吸入設備("SMI")基於差異化技術,可以有效提高吸入藥物的肺部沈積率。收購款項將由集團內部資源撥付。

事會認為,該收購具有以下戰略意義,符合公司及其股東的利益:

1.通過研發下一代吸入器技術為慢性阻塞性肺炎("COPD")和哮喘患者提供更有效的藥械合一產品,覆蓋不同的COPD患者羣體以補充集團現有的吸入藥械產品組合覆蓋範圍,鞏固集團在呼吸治療領域的領先地位。

2.收購及全面控制在呼吸類疾病藥物上的自主研發能力,推進集團從仿製到創新的轉變。Softhale擁有的自主知識產權與專利將支持該SMI技術的應用與拓展,具實現結合新化合物╱藥物並擴展到其他非呼吸治療領域的潛力。3.通過在歐洲建立本地樞紐並開發具有重大全球市場潛力的產品,加快集團的國際化戰略。

該收購中,集團聘請Results Healthcare(併購),Bakers Mc Kenzie(法律),Ernst & Young(財務和税務),Theraproval(監管)和Carpmaels & Ransford(知識產權)擔任顧問。

董事會相信,Softhale將成為集團業務在歐洲發展的關鍵戰略樞紐,並希望該公司發展為面向中國和全球市場的創新呼吸產品的領先開發商。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account